Eli Lilly’s obesity pill data; This week’s Q2 highlights; Biogen’s latest reinvention; and morenews2025-08-09T10:00:37+00:00August 9th, 2025|Endpoints News|
FDA restricts use of bluebird’s gene therapy due to increased cancer risknews2025-08-08T18:41:13+00:00August 8th, 2025|Endpoints News|
HHS official tasked with MAHA relations fired following mRNA cutsnews2025-08-08T18:15:12+00:00August 8th, 2025|Endpoints News|
FDA approves Boehringer’s pill for HER2-mutated lung cancernews2025-08-08T18:06:51+00:00August 8th, 2025|Endpoints News|
Assembly Bio touts Phase 1b success in herpes as Gilead buys 2.3M sharesnews2025-08-08T15:24:47+00:00August 8th, 2025|Endpoints News|
Gilead cuts several mid- and early-stage programsnews2025-08-08T15:10:27+00:00August 8th, 2025|Endpoints News|
Ipsen is no longer advancing Sutro’s ADC; Layoffs at Tune Therapeuticsnews2025-08-08T14:44:08+00:00August 8th, 2025|Endpoints News|
Bicycle Therapeutics lays off staff, Genentech partnership comes to an endnews2025-08-08T14:34:47+00:00August 8th, 2025|Endpoints News|
CureVac and GSK to receive money and royalties from BioNTech/Pfizer as part of mRNA patent settlementnews2025-08-08T14:05:04+00:00August 8th, 2025|Endpoints News|
Vor Bio hires former Sarepta exec to lead commercial strategy; Mallinckrodt poaches CFO from Incytenews2025-08-08T11:00:30+00:00August 8th, 2025|Endpoints News|
